LACOG - Latin American Cooperative Oncology Group
Research facility
Location:
Porto Alegre,
Brazil (BR)
ISNI: -
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial (2025)
Hortobagyi GN, Lacko A, Sohn J, Cruz F, Ruiz Borrego M, Manikhas A, Hee Park Y, et al.
Journal article
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)] (2024)
de Azambuja E, Piccart-Gebhart M, Fielding S, Townend J, Hillman DW, Colleoni M, Roylance R, et al.
Journal article
Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis (2024)
Untch M, Pérol D, Mayer EL, Cortes J, Nusch A, Cameron D, Barrios C, et al.
Journal article
Ribociclib plus Endocrine Therapy in Early Breast Cancer (2024)
Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, et al.
Journal article
Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: Pooled analysis of prospective neoadjuvant breast cancer (BC) trials (2019)
Werutsky G, Untch M, Hanusch C, Fasching P, Blohmer JU, Seiler S, Denkert C, et al.
Conference contribution